Allergan Third Quarter Earnings

By Investopedia Staff | October 30, 2012 AAA

Allergan (NYSE:AGN) announced its results for the most recent quarter on October 30, 2012. Allergan is a global specialty health care company. It discovers, develops, and commercializes innovative pharmaceuticals, biologics, and medical devices, as well as over-the-counter products.

Earnings season is important to investors because it shows how much profit is left in the company's hand after deducting costs from revenue. SEE: How To Decode A Company's Earnings Reports

The Numbers: Allergan's EPS outpaced analyst estimates while the company's revenues came in below predictions. The company reported adjusted net income of $1.06 per share versus the $1.04 per share estimate and revenues of $1.41 billion versus the $1.51 billion estimate. Revenue climbed 6.4% from the same period last year. Allergan's revenue has grown during each of the past four quarters on a year-over-year basis. The company's income has remained about on par with last year's levels.

Management Quote: "In the third quarter, Allergan again delivered solid earnings growth in spite of the strong U.S. Dollar relative to virtually all major currencies," said David E.I. Pyott, Allergan's Chairman of the Board, President and Chief Executive Officer. "In addition, we were pleased to mark the opening of our new R&D facility in New Jersey, as well as to announce the expansion of our relationship with Molecular Partners."

Looking Ahead: For next quarter, analysts have a more positive outlook about the company's expected results. The average estimate for the fourth quarter is $1.20 per share, up from $1.19 90 days ago. Increasing earnings estimate is a positive sign about the company and it typically leads a increase in the stock price. The average estimate for the fiscal year is $4.16 per share, down from $4.17 90 days ago.

You May Also Like

COMPANIES IN THIS ARTICLE
Related Analysis
  1. Stock Analysis

    Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog

  2. Stock Analysis

    AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog

  3. Chart Advisor

    Profit From Holiday Spending With This ETF

  4. Stock Analysis

    Novartis Successfully Expands Signifor Label in the U.S. - Analyst Blog

  5. Stock Analysis

    3 U.S. Medical Devices Stocks That Surged in 2014 - Analyst Blog

Trading Center